Document 3000
 DOCN  M94A3000
 TI    407 patients (pts) with AIDS-related non-Hodgkin's lymphoma (AIDS-NHL):
       the experience of the GICAT (Italian Cooperative Group on AIDS and
       Tumors).
 DT    9412
 AU    Tirelli U; Spina M; Vaccher E; Nasti G; Bernardi D; Serraino D;
       Rizzardini G; Fasan M; Division of Medical Oncology and AIDS, Centro di
       Riferimento; Oncologico, Aviano, Italy.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):176 (abstract no. PB0132). Unique
       Identifier : AIDSLINE ICA10/94369575
 AB    OBJECTIVE: To analyze the outcome of 407 pts with AIDS-NHL. METHODS:
       Since november 1986, we have collected data on 407 pts with peripheral
       AIDS-NHL observed by the GICAT. At the Aviano Cancer Center, in the same
       period of time 93 pts have been treated according to prospective
       protocols. Based on HIV-related prognostic factors pts with unfavourable
       histology and stage III and IV were treated with intensive third
       generation CT regimens (group 1, usually with CD4 > 200, good PS and
       without OI), with palliative CT with just 1 or 2 drugs or local RT
       (group 3, usually with CD4 < 100, poor PS and with OI) or with standard
       CHOP-like CT regimens (group 2, the remaining pts). RESULTS: At
       diagnosis of AIDS-NHL, CD4 < 100/mm3 were detected in 46% of the pts.
       Immunoblastic and Burkitt were diagnosed in 58% and 20% of the pts,
       respectively; advanced (III and IV) stage and B symptoms were present in
       80% and 69% of the pts, respectively. Median survival was 6 months; by
       the Cox model 4 factors were associated with a significantly shorter
       survival: advanced stage, heterosexuality, no treatment received and not
       having obtained a CR. The table reports the parameters that reached
       statistical significance in the comparison between the 3 groups of 92
       evaluable pts treated at the Aviano Cancer Center. TABULAR DATA, SEE
       ABSTRACT VOLUME. A significantly higher CR rate has been observed in
       group 1 pts, but with a concomitant increase of OIs during CT and follow
       up, in comparison to group 2 pts. However group 1 pts had a 1.5
       decreased risk of dying in comparison to group 2 and 3 pts. Overall, 13
       pts with a CR lasting for at least 2 years had a 42-month median
       survival with none of such pts relapsing even after 6 years. DISCUSSION
       AND CONCLUSIONS: We have observed a large number of peripheral AIDS-NHL,
       mainly with immunoblastic and Burkitt subtypes, advanced stage and B
       symptoms. In the prospective treatment at a single institution,
       intensive CT regimens were associated both to higher CR rate and higher
       OIs during CT and follow up, with some pts experiencing long survival
       and possibly cure.
 DE    Acquired Immunodeficiency Syndrome/*DRUG THERAPY/MORTALITY/
       PATHOLOGY/RADIOTHERAPY  Antineoplastic Agents, Combined/*THERAPEUTIC USE
       Combined Modality Therapy  Comparative Study  Follow-Up Studies  Human
       Italy  Leukocyte Count  Lymphoma, AIDS-Related/*DRUG
       THERAPY/MORTALITY/PATHOLOGY/  RADIOTHERAPY  Neoplasm Staging  Palliative
       Treatment  Prospective Studies  Support, Non-U.S. Gov't  Survival Rate
       T4 Lymphocytes/IMMUNOLOGY  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).